Hutchison China MediTech (HCM) Priced

CK Hutchison-backed pharmaceutical with a pipeline of oncology candidates.

Health Care - Biotechnology

IPO Performance
Latest Trade $13.34 0.00 (0.0%)
First Day Return -0.7%
Return from IPO -1.2%
 
Hutchison China MediTech IPO News more
  • .
IPO Data
IPO File Date 10/16/2015
Offer Price $13.50
Price Range $13.50 - $13.50
Offer Shares (mm) 7.5
Deal Size ($mm) 101
 
IPO Data
IPO Date 03/16/2016
Offer Price $13.50
Price Range $13.50 - $13.50
Offer Shares (mm) 7.5
Deal Size ($mm) $101
 
Underwriters
more
Business Overview
We are an innovative biopharmaceutical company based in China aiming to become a global leader in the discovery, development and commercialization of targeted therapies for oncology and immunological diseases. We have created a broad portfolio of drug candidates targeting eight molecular targets. We have taken a chemistry-focused approach to develop highly selective small molecule tyrosine kinase inhibitors that are intended to have potentially global best-in-class efficacy and are deliberately engineered to improve drug exposure, reduce known class-related toxicities and allow different drug therapies to be combinable.
We are an innovative biopharmaceutical company based in China aiming to become a global leader in the discovery, development and commercialization of targeted therapies for oncology and immunological diseases. We have created a broad portfolio of drug candidates targeting eight molecular targets. We have taken...
more
Company Data
Headquarters Hong Kong, , Hong Kong
Founded 2000
Employees 475
Website www.chi-med.com
 

Performance vs. IPO Index (IPOUSA)